DCGI grants restricted EUA for Corbevax for 12-18 yrs age group

Biological E Limited’s Corbevax vaccine, India’s first indigenously developed Receptor Binding Domain (RBD) protein sub-unit vaccine against Covid-19, has received emergency use authorization (EUA) from India’s drug regulator for the 12 to 18 years age group.

The Drugs Controller General of India (DCGI) approved Corbevax for restricted use in emergency situations among adults on December 28, 2019.

BE received the approval for restricted use in an emergency situation in adolescents aged 12 to less than 18 years, based on interim results of the ongoing phase II/III clinical study.

READ | Govt panel recommends EUA for BE’s Covid jab Corbevax for 12-18 yrs age group

Mahima Datla, managing director, Biological E. Limited, said, “We are pleased with this significant development, which helps extend the reach of our vaccine to the age group of 12 to 18 years in our country. We truly believe that with this approval, we are even closer to finishing our global fight against the pandemic. Once fully vaccinated, children can resume their activities and educational pursuits in schools and colleges without any apprehension. We thank all the participants in the clinical trials, Biotechnology Industry Research Assistance Council (BIRAC) and Department of Biotechnology, Translational Health Science and Technology Institute (TSTHI) and the principal investigators and clinical site staff who have extended their support during the last several months “

Last September, BE received approval to conduct a Phase II/III clinical trial of Corbevax in children and adolescents aged 5 to 18 years. Based on the no-objection certificate, BE initiated the clinical study in October 2021 and evaluated the available safety and immunogenicity results of the ongoing phase II/III study, which indicated that the vaccine is safe and immunogenic.

ALSO READ | Covid-19: What we learn from Omicron wave

The Corbevax vaccine is administered via intramuscular route with two doses scheduled 28 days apart and is stored at 2 to 8 degrees Celsius.

BE conducted phase I/II, II/III clinical trials of its Corbevax vaccine for adults in the country. In addition, it conducted a phase III active comparison clinical trial to evaluate superiority over the Covishield vaccine.